The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Integrin αvβ3‐targeted cancer therapy
Open accessAbstract
Anti‐angiogenesis is a promising strategy for the treatment of cancer. Integrins, consisting of two noncovalently bound transmembrane α and β subunits, are an important molecular family involved in tumor angiogenesis. The blockade of integrin signaling has been demonstrated to be efficient to inhibit tumor growth, angiogenesis, and metastasis. Among all the integrins, α v β 3 seems to be the most important one during tumor angiogenesis. The inhibition of integrin α v β 3 signaling with antibodies, peptides, peptidomimetics, and other antagonists has great potential in the treatment of cancer. In addition, integrin α v β 3 is highly expressed on activated endothelial cells, new‐born vessels as well as some tumor cells, but is not present in resting endothelial cells and most normal organ systems, making it a suitable target for anti‐angiogenic therapy. In this article we will review the role of integrin α v β 3 in angiogenesis, present recent progress in the use of integrin α v β 3 antagonists and integrin‐targeted delivery systems as potential cancer therapeutics, and discuss future perspectives. Drug Dev Res 69:329–339, 2008. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 2×
“[Jain, 2005].”
BackgroundRequirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
Role of angiogenesis in tumor growth and metastasis
Folkman, J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.37263 · Cited by 2,404
Role of angiogenesis in tumor growth and metastasis
FOLKMAN, J. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70065-1 · Cited by 2,400
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,264
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Role of integrins in cell invasion and migration
Hood, J. D., & Cheresh, D. A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc727 · Cited by 1,777
Integrin signalling during tumour progression
Guo, W., & Giancotti, F. G. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1490 · Cited by 1,471
Arg-Gly-Asp: A versatile cell recognition signal
Ruoslahti, E., & Pierschbacher, M. D. (1986) · Cell · doi:10.1016/0092-8674(86)90259-x · Cited by 1,397
Definition of Two Angiogenic Pathways by Distinct α v Integrins
Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., & Cheresh, D. A. (1995) · Science · doi:10.1126/science.270.5241.1500 · Cited by 1,321
RNA interference in adult mice
McCaffrey, A. P., Meuse, L., Pham, T.-T. T., Conklin, D. S., Hannon, G. J., & Kay, M. A. (2002) · Nature · doi:10.1038/418038a · Cited by 1,059
Function and interactions of integrins
van der Flier, A., & Sonnenberg, A. (2001) · Cell and Tissue Research · doi:10.1007/s004410100417 · Cited by 1,039
Schiffelers, R. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh140 · Cited by 901
Tumor Regression by Targeted Gene Delivery to the Neovasculature
Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., & Cheresh, D. A. (2002) · Science · doi:10.1126/science.1070200 · Cited by 858
Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.
Brooks, P. C., Strömblad, S., Klemke, R., Visscher, D., Sarkar, F. H., & Cheresh, D. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118227 · Cited by 828
Integrins: roles in cancer development and as treatment targets
Jin, H., & Varner, J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601576 · Cited by 574
Cheresh, D. A. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.18.6471 · Cited by 561
Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri
Scarborough, R. M., Rose, J. W., Hsu, M. A., Phillips, D. R., Fried, V. A., Campbell, A. M., Nannizzi, L., & Charo, I. F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)92826-7 · Cited by 371
Gutheil, J. C., Campbell, T. N., Pierce, P. R., Watkins, J. D., Huse, W. D., Bodkin, D., & Cheresh, D. A. (2000) · PubMed · Cited by 369
Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus.
Gan, Z. R., Gould, R. J., Jacobs, J. W., Friedman, P. A., & Polokoff, M. A. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)77710-2 · Cited by 368
Schwartz, M. A. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(01)02152-3 · Cited by 356
Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen, M. L., Oyen, W. J. G., Dijkgraaf, I., Massuger, L. F. A. G., Frielink, C., Edwards, D. S., Rajopadhye, M., Boonstra, H., Corstens, F. H. M., & Boerman, O. C. (2002) · PubMed · Cited by 331
Huang, T. F., Holt, J. C., Lukasiewicz, H., & Niewiarowski, S. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47710-1 · Cited by 324
Phase I and Correlative Biology Study of Cilengitide in Patients With Recurrent Malignant Glioma
Nabors, L. B., Mikkelsen, T., Rosenfeld, S. S., Hochberg, F., Akella, N. S., Fisher, J. D., Cloud, G. A., Zhang, Y., Carson, K., Wittemer, S. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6514 · Cited by 290
Dennis, M. S., Henzel, W. J., Pitti, R. M., Lipari, M. T., Napier, M. A., Deisher, T. A., Bunting, S., & Lazarus, R. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2471 · Cited by 282
Integrin αvβ3 as a Therapeutic Target for Blocking Tumor-Induced Angiogenesis
Kumar, C. (2003) · Current Drug Targets · doi:10.2174/1389450033346830 · Cited by 280
Tam, S. H., Sassoli, P. M., Jordan, R. E., & Nakada, M. T. (1998) · Circulation · doi:10.1161/01.cir.98.11.1085 · Cited by 260
Anti-Angiogenic Cancer Therapy Based on Integrin αvβ3 Antagonism
Cai, W., & Chen, X. (2006) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152006778226530 · Cited by 235
Self-citationWilder, R. L. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii96 · Cited by 232
Trikha, M., Zhao, Z., Tı́már, J., Raso, E., Kennel, M., Emmell, E., & Nakada, M. T. (2002) · PubMed · Cited by 210
Burke, P. A., DeNardo, S. J., Miers, L. A., Lamborn, K. R., Matzku, S., & DeNardo, G. L. (2002) · PubMed · Cited by 209
αvβ3 and αvβ5 integrin antagonists inhibit angiogenesis in vitro
Nisato, R. E., Tille, J.-C., Jonczyk, A., Goodman, S. L., & Pepper, M. S. (2003) · Angiogenesis · doi:10.1023/b:agen.0000011801.98187.f2 · Cited by 207
Abdollahi, A., Griggs, D. W., Zieher, H., Roth, A., Lipson, K. E., Saffrich, R., Gröne, H.-J., Hallahan, D. E., Reisfeld, R. A., Debus, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1223 · Cited by 205
CALVETE, J. J., MORENO-MURCIANO, M. P., THEAKSTON, R. D. G., KISIEL, D. G., & MARCINKIEWICZ, C. (2003) · Biochemical Journal · doi:10.1042/bj20021739 · Cited by 199
Taga, T., Suzuki, A., Gonzalez‐Gomez, I., Gilles, F. H., Stins, M., Shimada, H., Barsky, L., Weinberg, K. I., & Laug, W. E. (2002) · International Journal of Cancer · doi:10.1002/ijc.10265 · Cited by 198
Posey, J. A., Khazaeli, M. B., DelGrosso, A., Saleh, M. N., Lin, C. Y., Huse, W., & LoBuglio, A. F. (2001) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497801300189218 · Cited by 190
Cianfrocca, M. E., Kimmel, K. A., Gallo, J., Cardoso, T., Brown, M. M., Hudes, G., Lewis, N., Weiner, L., Lam, G. N., Brown, S. C., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603171 · Cited by 184
Kumar, C. C., Malkowski, M., Yin, Z., Tanghetti, E., Yaremko, B., Nechuta, T. L., Varner, J. A., Liu, M., Smith, E. M., Neustadt, B. R., et al. (2001) · PubMed · Cited by 172
In vivo therapy of malignant melanoma by means of antagonists of alphav integrins.
Mitjans, F., Meyer, T., Fittschen, C., Goodman, S. L., Jonczyk, A., Marshall, J. F., Reyes, G., & Piulats, J. (2000) · PubMed · Cited by 171
Vascular Integrins in Tumor Angiogenesis: Mediators and Therapeutic Targets
Alghisi, G. C., & Rüegg, C. (2006) · Endothelium · doi:10.1080/10623320600698037 · Cited by 159
Trikha, M., Zhao, Z., Nemeth, J. A., Chen, Q., Sharp, C. M., Emmell, E., Giles-Komar, J. M., & Nakada, M. T. (2004) · International Journal of Cancer · doi:10.1002/ijc.20116 · Cited by 155
Shebuski, R. J., Ramjit, D. R., Bencen, G. H., & Polokoff, M. A. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)88220-9 · Cited by 149
Mullamitha, S., Ton, N. C., Parker, G. J. M., Jackson, A., Julyan, P. J., Roberts, C., Buonaccorsi, G. A., Watson, Y., Davies, K. E., Cheung, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2779 · Cited by 146
MacDonald, T. J., Stewart, C. F., Koçak, M., Goldman, S., Ellenbogen, R. G., Phillips∥, P. C., Lafond, D. A., Poussaint, T. Y., Kieran, M. W., Boyett, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1812 · Cited by 144
Stepwise in vitro affinity maturation of Vitaxin, an α v β 3 -specific humanized mAb
Wu, H., Beuerlein, G., Nie, Y., Smith, H., Lee, B. A., Hensler, M. E., Huse, W. D., & Watkins, J. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6037 · Cited by 143
Mitjans, F., Sander, D., Adan, J., Sutter, A., Martinez, J. M., Jaggle, C. S., Moyano, J. M., Kreysch, H. G., Piulats, J., & Goodman, S. L. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.8.2825 · Cited by 135
Hariharan, S., Gustafson, D. L., Holden, S. N., McConkey, D. J., Davis, D. W., Morrow, M., Basche, M., Gore, L., Zang, C., O’Bryant, C. L., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm140 · Cited by 130
Swenson, S. D., Costa, F. K., Minea, R. O., Sherwìn, R. P., Ernst, W. A., Fujii, G., Yang, D., & Markland, F. S. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.499.3.4 · Cited by 112
Carron, C., Meyer, D. M., Pegg, J. A., Engleman, V. W., Nickols, M. A., Settle, S. L., Westlin, W., Ruminski, P. G., & Nickols, G. A. (1998) · PubMed · Cited by 107
What have snakes taught us about integrins?
Huang, T. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050181 · Cited by 106
Delbaldo, C., Raymond, É., Vera, K., Hammershaimb, L., Kaucic, K., Lozahic, S., Marty, M. E., & Faivre, S. J. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9077-0 · Cited by 101
Chen, Q., Manning, C. D., Millar, H. J., McCabe, F. L., Ferrante, C. A., Sharp, C. M., Shahied-Arruda, L., Doshi, P. D., Nakada, M. T., & Anderson, G. M. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9132-4 · Cited by 92
Doñate, F., Parry, G. C., Shaked, Y., Hensley, H. H., Guan, X., Beck, I., Tel-Tsur, Z., Plunkett, M. L., Manuia, M., Shaw, D. E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4530 · Cited by 92
Raguse, J.-D., Gath, H. J., Bier, J., Riess, H. B., & Oettle, H. (2003) · Oral Oncology · doi:10.1016/j.oraloncology.2003.08.003 · Cited by 87
Angiogenesis as a biomarker and target in cancer chemoprevention
Sharma, R. A., Harris, A. L., Dalgleish, A. G., Steward, W. P., & O'Byrne, K. J. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00586-1 · Cited by 86
Tumor Vascular Targeting with Tumor Necrosis Factor α and Chemotherapeutic Drugs
Corti, A., & Ponzoni, M. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1322.011 · Cited by 85
Harris, T. D., Kalogeropoulos, S., Nguyen, T., Liu, S., Bartis, J., Ellars, C. E., Edwards, S., Onthank, D. C., Silva, P., Yalamanchili, P., et al. (2003) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497803322287727 · Cited by 82
Beekman, K. W., Colevas, A. D., Cooney, K. A., DiPaola, R. S., Dunn, R. L., Gross, M. E., Keller, E. T., Pienta, K. J., Ryan, C. J., Smith, D. C., et al. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.n.012 · Cited by 80
Integrin αvβ3-Targeted Radioimmunotherapy of Glioblastoma Multiforme
Veeravagu, A., Liu, Z., Niu, G., Chen, K., Jia, B., Cai, W., Jin, C., Hsu, A. R., Connolly, A. J., Tse, V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0797 · Cited by 80
Self-citationEnhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature
Cao, L., Du, P., Jiang, S.-H., Jin, G., Huang, Q.-L., & Hua, Z. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0533 · Cited by 71
Doxorubicin-formaldehyde conjugates targeting alphavbeta3 integrin.
Burkhart, D. J., Kalet, B. T., Coleman, M. P., Post, G. C., & Koch, T. H. (2004) · PubMed · Cited by 69
Meerovitch, K., Bergeron, F., Leblond‐Larouche, L., Grouix, B., Poirier, C., Bubenik, M. P., Chan, L. C., Gourdeau, H., Bowlin, T. L., & Attardo, G. (2003) · Vascular Pharmacology · doi:10.1016/s1537-1891(02)00339-7 · Cited by 65
Sacchi, A., Gasparri, A. M., Curnis, F., Bellone, M., & Corti, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1445 · Cited by 65
Doxorubicin-formaldehyde conjugates targeting αvβ3 integrin
Burkhart, D. J., Kalet, B. T., Coleman, M. P., Post, G. C., & Koch, T. H. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1593.3.12 · Cited by 64
Zarovni, N., Monaco, L., & Corti, A. (2004) · Human Gene Therapy · doi:10.1089/104303404322959524 · Cited by 55
Integrin αvβ3‐targeted therapy for Kaposi's sarcoma with an in vitro‐evolved antibody
Rader, C. M., Popkov, M., Neves, J. A., & Barbas, C. F. (2002) · The FASEB Journal · doi:10.1096/fj.02-0281fje · Cited by 53
Carron, C. P., Meyer, D. M., Engleman, V. W., RICO, J. G., Ruminski, P. G., Ornberg, R., Westlin, W., & Nickols, G. A. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1650587 · Cited by 52
Cohen, S. A., Trikha, M., & Mascelli, M. A. (2000) · Pathology & Oncology Research · doi:10.1007/bf03032368 · Cited by 47
van Laarhoven, H. W. M., Gambarota, G., Heerschap, A., Lok, J., Verhagen, I., Corti, A., Toma, S., Stampino, C. G., van der Kogel, A., & Punt, C. J. A. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-4540-2 · Cited by 46
Varner, J. A., Nakada, M. T., Jordan, R. E., & Coller, B. S. (1999) · Angiogenesis · doi:10.1023/a:1009019223744 · Cited by 44
Smith, J. W. (2003) · PubMed · Cited by 43
Strieth, S., Eichhorn, M., Sutter, A., Jonczyk, A., Berghaus, A., & Dellian, M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21838 · Cited by 38
The Application of siRNA Technology to Cancer Biology Discovery
Fuchs, U., & Borkhardt, A. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)96004-7 · Cited by 35
New Insights on Disintegrin-Receptor Interactions: Eristostatin and Melanoma Cells
McLane, M. A., Kuchar, M. A., Brando, C., Santoli, D., Paquette‐Straub, C., & Miele, M. E. (2001) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000048061 · Cited by 27
Cited by
Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., Cherif, H., Uddin, S., Steinhoff, M., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 618
Nanomaterials for Nanotheranostics: Tuning Their Properties According to Disease Needs
Wong, X. Y., Sena-Torralba, A., Álvarez-Diduk, R., Muthoosamy, K., & Merkoçi, A. (2020) · ACS Nano · doi:10.1021/acsnano.9b08133 · Cited by 363
Enzymatic fluorination and biotechnological developments of the fluorinase
O’Hagan, D., & Deng, H. (2015) · Chemical Reviews · doi:10.1021/cr500209t · Cited by 331
Low levels of physiological interstitial flow eliminate morphogen gradients and guide angiogenesis
Shirure, V. S., Lezia, A., Tao, A., Alonzo, L. F., & George, S. C. (2017) · Angiogenesis · doi:10.1007/s10456-017-9559-4 · Cited by 117
Integrins as a drug target in liver fibrosis
Rahman, S. R., Roper, J. A., Grove, J. I., Aithal, G. P., Pun, K. T., & Bennett, A. J. (2022) · Liver International · doi:10.1111/liv.15157 · Cited by 74
Metadata
- Authors
- Liu, Z., Wang, F., & Chen, X.
- Venue
- Drug Development Research
- Publisher
- Wiley
- Published
- 2008-09
- Volume
- 69
- Issue
- 6
- Pages
- 329-339
- ISSN
- 0272-4391 (ISSN-L)
- 1098-2299
- OpenAlex
- W2140859605
- Cited by
- 323
- References
- 78
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.